SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.930
+0.120 (4.27%)
Dec 3, 2024, 1:41 PM EST - Market open
SAB Biotherapeutics Revenue
SAB Biotherapeutics had revenue of $1.51M in the twelve months ending September 30, 2024, down -63.06% year-over-year. In the year 2023, SAB Biotherapeutics had annual revenue of $2.24M, down -90.63%.
Revenue (ttm)
$1.51M
Revenue Growth
-63.06%
P/S Ratio
16.03
Revenue / Employee
$26,539
Employees
57
Market Cap
27.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
Dec 31, 2019 | 3.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Equillium | 45.91M |
Bionano Genomics | 33.33M |
DarioHealth | 23.05M |
BioLineRx | 21.99M |
DURECT | 8.59M |
Co-Diagnostics | 7.32M |
NeurAxis | 2.46M |
CytoMed Therapeutics | 330.25K |
SABS News
- 26 days ago - SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 2 months ago - SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 3 months ago - SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewsWire
- 4 months ago - SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewsWire
- 4 months ago - SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewsWire
- 4 months ago - SAB BIO Appoints Lucy To as Chief Financial Officer - GlobeNewsWire
- 5 months ago - SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewsWire
- 6 months ago - SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - GlobeNewsWire